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1. Introduction 
The concept of inflammatory spondyloarthropathies (SpA) as an independent group of 
diseases was introduced approximately 15-20 years ago, when symptoms distinguishing 
these diseases from rheumathoid arthritis (RA) were defined precisely. SpA group includes 
4 main diseases: ankylosing spondylitis (AS), psoriatic arthritis (PsA), reactive arthritis 
(ReA) and enteropathic arthropathies (EnA). Global prevalence of these diseases is .2-3.0 
percent. Furthermore, SpA incidence in Lithuania is .64 percent (Adomaviciute et al., 2008).  
The incidence is higher in close relatives of patients with established human leucocyte 
antigen B27 (HLA B27). SpA is 2-3 times more common in males than in females ( Khan, 
2002; Sieper, 2002).  
Although SpA and RA ethiology and pathogenesis differ, these immune arthritides are 
similar in their consequences, principles of diagnostic and treatment. Genetic predisposition 
to the disease and relation with infectious factors is characteristic to both SpA and RA 
diseases, however, the true causes remain unclear. It is known that tissue damage in these 
diseases is caused by reactions governed by immune processes. In addition, RA is the most 
investigated autoimmune, continuously progressing erosive-destructive poliarthritis. The 
incidence among adults ranges from .35 to 1.0 percent in various populations whilst in 
Lithuania it is about .55 percent (Adomavičiūtė et al., 2008). In both SpA and RA clinical 
outcomes depend primarily on various complications: cardiovascular abnormalities, 
infections, amyloidosis, osteoporosis. 
Osteoporosis (OP) is a skeletal disease characterized by low bone mineral density (BMD) 
and poor bone quality that reduces bone strength and increases the risk of fractures. OP is a 
major public health concern, affecting approximately 200 million individuals worldwide, 
including a third of women aged 60 to 70 years. Fractures of the hip and spine are associated 
with increased morbidity and mortality (Johnell et al., 2005). Despite the high prevalence of 
OP and the availability of effective drugs to reduce the risk of fracture, it is underdiagnosed 
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and undertreated (Feldstein et al., 2003). Patients with immune arthritides, who are at very 
high risk of fracture, are usually not evaluated for OP. It has been reported that in patients 
with SpA and RA decreased BMD is being diagnosed at a much younger age (Lane at al., 
2002). These patients are affected not only by ordinary OP risk factors but also specific 
disease factors: activity and course of the disease, its duration, treatment with 
glucocorticoids (GC) and immunosuppressants, reduced mobility (Gratacos, 1999; Kroot, 
2001; Baek, 2005).  
Most of the publications analyzing BMD changes are related to RA. It was observed that RA 
is associated with local and systemic loss of bone mineral density (Sambrook, 1995; Gough, 
1994) and also with increased risk of osteoporotic fracture (Cooper et al., 1995). The main 
factors associating RA and decrease of BMD are activity of the disease, physical disability 
and immobility, disease duration and use of gliucocorticoids (Dequeker, 1995; Kvien, 2000). 
According to other work in the field, pathologic fractures of spine vertebrae are more 
common in patients with SpA than RA (despite the formation of syndesmophytes and 
ossification of longitudinal ligaments that could probably “protect the spine” in SpA case) 
(Bessant, 2002; Brand, 2008). It is supposed that in both RA and SpA bone tissue is damaged 
due to reduced mobility, the activity of the disease and, most importantly, similar reactions 
caused by immune processes, which are characteristic to these diseases (Illei et al., 2000; 
Pettit, 2001). 
Although in most cases SpA are investigated as a whole group of diseases with common 
clinical, radiological and genetic features, BMD was investigated mostly in patients with AS. 
According to other studies, the incident of OP in patients with AS is very different and 
ranges from 50 to 92%  (Mitra, 2000; Capaci, 2003). Too little and controversial data 
concerning changes of BMD in other diseases belonging to SpA group were published (El 
Maghraoui, 2004; Speden, 2002).  
Scientific novelty. This investigation for the first time evaluated and compared BMD at the 
lumbar spine and upper part of left and right femur in patients with SpA and RA and 
healthy people. Consistent patterns of BMD changes at the lumbar spine and upper parts of 
both femurs were assessed in patients with diseases belonging to SpA group (AS, ReA, EnA, 
PsA) and in SpA patients with various types of joint lesion. Relation between SpA specific 
factors – duration of the disease, physical disability and immobility, activity of the disease, 
medications in use and BMD changes at the lumbar spine and upper part of left and right 
femur was evaluated. 
Absolute determination of consistent patterns of BMD changes at the lumbar spine and 
upper parts of both femurs in patients with various diseases belonging to SpA group (AS, 
ReA, EnA, PsA) and with various types of joint lesion together with, investigation of distinct 
clinical risk factors associated with BMD changes in SpA patients would allow to select 
patients for BMD test precisely, indicate the exact skeleton area for investigation, diagnose 
changes in bone mass earlier and timely apply effective preventive and/or treatment 
measures. 
Aim of the research – to determine consistent patterns of BMD changes at the lumbar spine 
and upper part of left and right femur in patients with SpA (AS, ReA, PsA, EnA) and to 
assess the relation between changes of BMD and specific factors of the disease (duration of 
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the disease, physical disability and immobility, activity of the disease, medications in use) 
using noninvasive method of BMD evaluation (dual-energy X-ray absorptiometry (DXA)). 
Objectives of the research 
 To investigate BMD changes at the lumbar spine and upper part of left and right femur 
in groups of patients with SpA, Ra and healthy subjects.  
 To investigate BMD changes at the lumbar spine and upper part of left and right femur 
in patients with various diseases belonging to SpA group (AS, ReA, PsA, EnA) and in 
SpA patients with different type of joint lesions (only axial, only peripheral, both axial 
and peripheral).  
 To analyse relation between the duration of SpA and BMD changes at the lumbar spine 
and upper part of left and right femur.  
 To evaluate influence of physical disability and immobility on BMD changes in patients 
with SpA. 
 To determine influence of medications in use: glucocorticoids and TNF- blockers on 
BMD changes in patients with SpA. 
Statements defended: 
 BMD decrease at the lumbar spine and upper part of left and right femur is similar in 
patients with inflammatory joint diseases: SpA and RA. 
 Impact of various diseases belonging to SpA group on bone mass changes is similar. 
 SpA activity and physical disability and immobility are important prognostic factors for 
BMD decrease. 
2. Study subjects and methods 
2.1 Study population 
Patients treated in the Department of Rheumatology of Vilnius University Hospital 
“Santariškių klinikos” in the period of December 2006 to June 2008 were invited to 
participate in this research. Patients arriving at Vilnius University Hospital “Santariškių 
klinikos” Family Health Center for the prophylactic examination were invited to take part in 
the control group of the research. A total of 136 patients with SpA, 104 patients with RA and 
114 healthy people (control group) matching inclusion criteria, and not having any exclusion 
criteria stated below were involved in the investigation. 
2.2 Inclusion criteria 
 Age of subjects ranging from 20 to 75 years; 
 People with RA diagnosis established according to rheumatoid arthritis diagnostic 
criteria of American College of Rheumatology (ARA’87) (diagnosis established by 
rheumatologist) ( Arnett et al., 1988); 
 Subjects with SpA diagnosis established according to diagnostic criteria approved by 
European Spondyloarthropathy Study Group (ESSG) (1991) (diagnosis established by 
rheumatologist);  
 Subjects of control group – healthy individuals (Dougados et al., 1991); 
 Subjects signed an Informed Consent form approved by Lithuanian bioethics committee. 
(The permission to perform this investigation was obtained from the Lithuanian 
bioethics committee (No.60; 2006-12-22)). 
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2.3 Exclusion criteria 
 Subjects after hip joint replacement; 
 Patients with other diseases (renal, liver, thyroid and parathyroid, and cancer) 
influencing calcium metabolism or interfering metabolism of bone tissue; 
 Individuals treated with medications (anti-osteoporosis, thyroxin, insulin, 
anticoagulants, anticonvulsants, hormone replacement therapy, etc.) that may influence 
bone tissue metabolism, except medications used to treat underlying disease: disease 
modifiers, TNF-α blockers, GC and non-steroid anti-inflammatory drugs (data obtained 
from medical records and patient interviews); 
 Pregnant women, vegetarians, alcohol addicts. 
2.4 Research structure 
Primary selection of patients was performed according to patients' medical history and 
data of clinical investigations (data from the hospital and out-patient records were used 
under the patients consent). Then, every patient completed one of the three questionnaires 
depending on the research subgroup he/she belonged to. The following questionnaire 
data were assessed: socio-demographic data – age, gender, education, profession, work 
environment; smoking, use of alcohol; bone fractures in subject and his close relatives; 
previous and current diseases; previously and currently used medications; calcium 
amount in the diet (mg/d); frequency of physical activities by month (at least 20 minutes 
physical exercises per day) and the age of the beginning and the end of menstrual cycle in 
femails. 
In patients with SpA and RA: duration of the disease (in months) from the onset of the first 
symptoms and from the date the diagnosis was established; pain intensity assessment using 
10 cm VAS scale; patient’s general status assessment using 10 cm VAS scale.  
In patients with SpA the following parameters were assessed: disease belonging to SpA 
group; type of joint lesion: axial, peripheric, both axial and peripheric; physical disability 
was assessed by completing Health Assessment Questionaire Modified for 
Spondyloarthropathies (HAQ-S) (Daltroy et al., 1990); immobility was assessed according to 
Bath Ankylosing Spondylitis Functional Index (BASFI) (Calin et al., 1994) and Bath 
Ankylosing Spondylitis Patient Global Score (BAS-G) (Jones et al., 1996); assessment of 
enthesis; movement of spine was assessed according to standardized SpA clinical 
measurements: lumbar side flexion, modified Schober’s test, tragus to wall distance and 
intermalleolar distance (Jenkinson et al, 1994); activity of the disease according to patients 
self-assessment using Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 
(Garrett et al, 1994); activity of the disease evaluated by rheumatologist (Landewe et al, 
2004). The linguistic and cultural adaptation of these questionnaires was made during the 
study. Internal consistency was high for functional and disease activity index (Cronbach 
alpha>/=0.80) and moderate for the Bath Ankylosing Spondylitis Patient Global Score 
(Cronbach alpha=0.58). High stability in regard to time was characteristic of all three 
questionnaires (intraclass correlation coefficient >0.95). A significant association between the 
separate questions of examined instruments, their joint results and other factors reflecting 
patient's health was established (Venceviciene et al., 2009). 
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In patients with RA the following parameters were assessed: rheumatoid arthritis functional 
ARA classes; disease activity index DAS 28 and activity of the disease established by 
rheumatologist (Arnett et al., 1988). 
Anthropometric measurements were performed on all patients: height, weight, BMI; 
laboratory tests: ESR, CRP, calcium blood level, HLA-B27 (in patients with SpA), RF (in 
patients with RA). Laboratory tests were performed in the Department of Laboratory 
Diagnostics of Vilnius University Hospital “Santariškių klinikos”. 
2.5 Evaluation of the bone mineral density 
In all subjects BMD was measured by dual-energy X-ray absorptiometry (DXA) using 
osteodensitometer LEXXOS-DMS (software: V6, 20a, version of the year 2006). The anterior-
posterior view of lumbar spine (L1-L4 vertebrae) and upper parts of both femurs were 
examined. BMD data were expressed as g/cm2 and the number of standard deviations from 
the peak bone mass (T – score), and also the number of standard deviations of any 
individual result from the age and sex matched population mean (Z – score). Normal ranges 
were provided by manufacturers of the osteodensitometer. According to ISCD 
recommendations, BMD deviation was measured as Z-score, since most of the enrolled 
subjects were males less than 50 years old. Osteodensitometer quality test and measurement 
error test were performed every morning before work. Indications of the scan of spine 
vertebrae reference (phantom) fluctuated no more than 2 %, bias of the repeated 
measurement in spine vertebrae was not higher than 1.5 %, and in the upper part of femur– 
not higher then 2.1 %. All BMD measurements were performed by the principal 
investigator. 
2.6 Data analysis 
Statistical analysis was performed using SPSS 16 software. Mean (M) and standard 
deviation (SD) were used to describe quantitative characteristics of the research. Frequencies 
(n) and percents (%) were used for qualitative characteristics. Depending on applicable 
assumptions Student’s t-test for independent samples was used to compare means of a 
particular qualitative characteristic of different samples. Analysis of variance ANOVA was 
used to compare quantitative variables of more than two samples (when variances were 
unequal Welch test statistics was used). When the hypothesis of the equality of means of 
two or more groups was rejected, pairwise comparison of this characteristic was 
additionally used. In that case Tukey HSD Post Hoc test was used. Differences of qualitative 
characteristics of experimental groups were assessed using Chi square test. Selected level of 
significance α = .05.  
To analyze relationship between SpA variables: the duration of disease, physical disability 
and immobility, activity of the disease and treatment with GC and TNF- blockers and 
BMD changes linear regression models were developed. Stepwise selection of variables in 
the linear regression was used. Variables were included in the model when their p was <.05 
and excluded when their p was > .10. When strong association between independent 
variables was observed (e.g., cumulative dose of GC and duration of use (calculated using 
Spearman correlation coefficient), only one of them was used for calculations. To assess 
probability that Z-score will be  -2 in any site of examined skeleton logistic regression 
analysis was used. 
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3. Results 
3.1 Characteristics of study groups 
Three hundred fifty four subjects were enrolled in this research: 136 (38.4%) patients with 
SpA, 104 (29.4%) patients with RA and 114 (32.2%) healthy people (control group). The 
subjects of all groups were similar in BMI, physical activity and family history (all p > .05). 
No differences in disease activity determined by rheumatologist were observed between RA 
and SpA patients (p > .516). Subjects’ differences in age (SpA patients: M = 42.18 ± 12.92; RA 
patients: M = 50.09 ± 11.10; p < .001), duration of the disease (SpA patients: M = 112.09 ± 
94.54; RA patients: M = 148.49 ± 109.60; p < .007), and gender were determined. There were 
more males in SpA group compared with RA group (p < .001) and control group (p < .001); 
there were no differences in the number of males in RA group and control group (p = .119). 
No significant differences in the proportion of premenopausal and postmenopausal women 
in research groups were determined. (SpA vs. control group p = .550; SpA vs. RA p = .112; 
RA vs. control group p = .600).  
3.2 BMD comparison in patients with SpA and RA and in control group subjects 
The first objective of our research was to investigate BMD changes at lumbar spine and 
upper parts of the femurs in groups of patients with SpA, RA and healthy subjects.  
BMD values at lumbar spine and upper part of the left and right femur (BMD expressed as 
g/cm2 and Z-score) are presented in Table 1. 
 
BMD 
Research groups 
p Post hoc 1 2 3 
SpA (n = 136) RA (n = 104) Control (n = 114) 
BMDS .873 (.128) .866 (.125) 1.016 (.121) < .001
3>1 (p <.001) 
3>2 (p <.001) 
BMDL .849 (.121) .832 (.131) .998 (.113) < .001
3>1 (p <.001) 
3>2 (p <.001) 
BMDR .837 (.122) .825 (.122) .983 (.110) < .001
3>1 (p <.001) 
3>2 (p <.001) 
ZS -1.317 (.998) -1.061 (1.096) .045 (.941) < .001
3>1 (p <.001) 
3>2 (p <.001) 
ZL -1.133 (.949) -1.014 (1.001) .097 (.842) < .001
3>1 (p <.001) 
3>2 (p <.001) 
ZR -1.222 (.952) -1.143 (1.161) -.014 (.838) < .001
3>1 (p <.001) 
3>2 (p <.001) 
Table 1. Comparison of BMD (g/cm2) and Z-score (mean (SD)) between research groups 
SpA – patients with spondyloarthropathies; RA – patients with rheumatoid arthritis. Bone 
mineral density (BMD) expressed as g/cm2 at spine (BMDS), left femur (BMDL) and right 
femur (BMDR); BMD expressed as Z-score in spine (ZS), left femur (ZL) and right femur 
(ZR). 
In both SpA and RA patients a similar decrease of BMD (expressed as g/cm2 and Z-score, 
unless otherwise stated) (Table 1) at lumbar spine and upper parts of the both femurs was 
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determined. It was also established that in both SpA and RA patients mean BMD value in all 
examined skeletal sites was significantly lower than mean BMD value in control group 
subjects. 
3.3 Homogenicity by BMD changes in patients with various diseases belonging to 
spondyloarthropathy group and with various types of joint lesions 
The second objective of our research was to investigate BMD changes at lumbar spine and 
upper part of the left and right femur in patients with various diseases belonging to SpA 
group (AS, ReA, PsA, EnA) and in SpA patients with different type of joint lesions (only 
axial, only peripheral, both axial and peripheral). 
Patients with SpA were allocated to the following subgroups: 54 (39.70%) patients with AS, 
33 (24.3%) – with PsA, 29 (21.3%) - with EnA and 20 (14.7%) with ReA. The comparison of 
BMD value between these groups is presented in Table 2. 
 
BMD 
Disease belonging to SpA group 
p 
AS (n = 54) PsA (n = 33) EnA (n = 29) ReaA (n = 20) 
BMDS .885 (.149) .890 (.143) .837 (.075) .870 (.096) .346 
BMDL .837 (.125) .845 (.135) .857 (.115) .877 (.094) .632 
BMDR .821 (.127) .830 (.131) .858 (.118) .860 (.094) .463 
ZS -1.301 (1.023) -1.077 (1.258) -1.631 (.484) -1.298 (.868) .179 
ZL -1.282 (.912) -.991 (1.069) -1.157 (.856) -.928 (.965) .392 
ZR -1.386 (.933) -1.120 (1.032) -1.158 (.891) -1.040 (.954) .418 
Table 2. Comparison of BMD (g/cm2) and Z-score (mean (SD)) between patients with 
various diseases of spondyloarthropathy group patients with ankylosing spondylitis (AS), 
psoriatic arthritis (PsA), reactive arthritis (ReA) and enteropathic arthropathy (EnA). Bone 
mineral density (BMD) expressed as g/cm2 at spine (BMDS), left femur (BMDL) and right 
femur (BMDR); BMD expressed as Z-score in spine (ZS), left femur (ZL) and right femur 
(ZR). 
Data presented in Table 2 do not demonstrate statistically significant BMD differences 
at lumbar spine and upper parts of the both femurs of patients with AS, PsA, EnA and 
ReA. 
Patients with SpA were allocated to three subgroups depending on the type of joint lesion: 
patients with only axial lesion, only peripheral lesions and patients with both axial and 
peripheral lesion. Twenty five (18.4%) patients were allocated to the axial lesion group, 20 
(14.7%) – to the peripheral lesion group, and both axial and peripheral lesion was diagnosed 
in 91 (66.9) patients. The comparison of BMD in SpA patients with various joint lesion types 
showed that there are no significant differences in BMD between subgroups at any 
examined sites of the skeleton (Table 3). 
Summarizing data presented in Tables 2 and 3 it might be claimed that no significant 
differences in BMD mean values were found at any examined sites of the skeleton both 
comparing patients with various diseases belonging to SpA group and patients with 
different types of joint lesions. Therefore SpA group could be further analyzed as a 
homogeneous group without dividing it into subgroups by diseases. 
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BMD 
Type of joint lesion 
p Axial 
(n = 25) 
Peripheric 
(n = 20) 
Axial and peripheric 
(n = 91) 
BMDS .859 (.158) .846 (.080) .883 (.128) .416 
BMDL .836 (.147) .882 (.100) .845 (.117) .391 
BMDR .818 (.149) .875 (.103) .833 (.117) .269 
ZS -1.427 (1.289) -1.541 (.668) -1.237 (.952) .384 
ZL -1.284 (1.122) -.982 (.874) -1.124 (.917) .567 
ZR -1.408 (1.142) -1.034 (.874) -1.213 (.913) .421 
 
Table 3. Comparison of BMD (g/cm2) and Z-score (mean (SD)) between patients with 
various types of joint lesions Bone mineral density (BMD) expressed as g/cm2 at spine 
(BMDS), left femur (BMDL) and right femur (BMDR); BMD expressed as Z-score in spine 
(ZS), left femur (ZL) and right femur (ZR). 
3.4 Variables associated with bone mineral density changes in patients with 
spondyloarthropathies 
In order to determine variables related to BMD at lumbar spine and upper part of the left 
and right femur of patients with SpA, 90 models of multiple stepwise linear regression 
analysis were developed. One of the values of BMD (BMDS, BMDL, BMDR, ZS, ZL, ZR) 
served as dependent variable, and independent variables were controlled variables: age, 
gender (when BMD was expressed as g/cm2), BMI, family history of fractures, various 
diseases belonging to SpA group, type of joint lesions and physical activity. Each time one of 
the specific SpA factors was involved into the model: duration of the disease calculated from 
the time of the manifestation of first symptoms and from the time the diagnosis was 
established; physical disability and immobility indicators: subjective (HAQ-S, BAS-G, 
BASFI) and objective (spine movement indicators: lumbar side flexion, modified Schober’s 
test, tragus to wall distance and intermalleolar distance); disease activity indicators: 
BASDAI, ESR, CRP and disease activity determined by rheumatologist; medications in use: 
glucocorticoids and TNF- blockers. Variables with highest determination coefficients of the 
equations of multiple stepwise linear regression obtained during the assessment of BMD at 
lumbar spine and upper part of the left and right femur were selected for the final multiple 
linear regression analysis: 
 Age, gender (BMD expressed as g/cm2), BMI; 
 Duration of the disease calculated from the time of the manifestation of first symptoms; 
 Indicators of patient’s functional status: physical disability and immobility according to 
HAQ-S questionnaire, and reduction of spine movement assessed by the measurement 
of intermalleolar distance; 
 Activity of the diseases determined by rheumatologist; 
 Treatment: cumulative doses of glucocorticoids (g). 
The summary of the final linear regression analysis model is presented in Table 4. Coding of 
the categorical variables is presented in Table 5. 
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Dependent 
variable 
Independent variable 
Regression coefficient (B) 
(standard error) 
Beta p 
BMDS 
(R2 =.192; 
R2 (adj.) = .168; 
p < .001) 
DAR2 -.124 (.027) -.459 < .001 
DAR1 -.066 (.026) -.252 .012 
G2 .064 (.023) .231 .006 
BMI .005 (.002) .189 .022 
constant .773 (.063)  < .001 
BMDL 
(R2 =.405; 
R2 (adj.) = .382; 
p < .001) 
DAR2 -.122 (.022) -.480 < .001 
IM2 -.101 (.025) -.290 < .001 
BMI .006 (.002) .244 .001 
DAR1 -.059 (.021) -.240 .005 
Glucocorticoids -.001 (.001) -.141 .045 
Constant .783 (.047)  < .001 
BMDR 
(R2 =.443; 
R2 (adj.) = .421; 
p < .001) 
DAR2 -.115 (.022) -.450 < .001 
IM2 -.121 (.024) -.347 < .001 
BMI .006 (.002) .230 .001 
Glucocorticoids -.002 (.001) -.163 .017 
DAR1 -.046 (.020) -.185 .025 
Constant .775 (.046)  < .001 
ZS 
(R2 =.294; 
R2 (adj.) = .266; 
p < .001) 
BMI .061 (.015) .313 < .001 
DAR2 -.919 (.196) -.441 < .001 
DAR1 -.496 (.185) -.247 .008 
Duration of the disease from 
first symptoms onset 
.003 (.001) .252 .003 
Glucocorticoids -.019 (.007) -.226 .006 
Constant -2.608 (.418)  < .001 
ZL 
(R2 =.388; 
R2 (adj.) = .365; 
p < .001) 
DAR2 -.922 (.177) -.461 < .001 
BMI .072 (.013) .384 < .001 
DAR1 -.468 (.165) -.243 .005 
Glucocorticoids -.012 (.006) -.146 .042 
IM2 -.400 (.199) -.147 .046 
Constant -2.399 (.373)  < .001 
ZR 
(R2 =.384 
R2 (adj.) = .360; 
p < .001) 
DAR2 -.853 (.178) -.425 < .001 
BMI .068 (.013) .360 < .001 
IM2 -.550 (.200) -.201 < .001 
Glucocorticoids -.013 (.006) -.160 .007 
DAR1 -.366 (.166) -.189 .026 
Constant -2.414 (.376)  < .001 
Table 4. Multiple linear regression analysis of BMD (expressed as g/cm2 and Z-score) at 
different sites of measurement (dependent variable), demographic and disease variables 
(independent variables). Bone mineral density (BMD) expressed as g/cm2 at spine (BMDS), 
left femur (BMDL) and right femur (BMDR); BMD expressed as Z-score at spine (ZS), left 
femur (ZL) and right femur (ZR). IM – intermalleolar distance; DAR - activity of the disease 
determined by rheumatologist. The coefficient of determination R2 and coefficient of 
determination corrected by the number of independent variables (R2(adj.)), and p value 
close to the coefficient of determination is intended to test the hypothesis that regression is 
absent (hypothesis is discarded when p < .05); standard error determines standard deviation 
of the coefficient of regression; beta determines coefficient of regression of standardized 
data. 
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Variable Coding 
Gender G1 G2 
Premonapausal females 0 0 
Postmenopausal females 1 0 
Males 0 1 
Intermalleolar distance IM1 IM2 
0 – mild limitation of movement 0 0 
1 – moderate limitation of movement 1 0 
2 – severe limitation of movement 0 1 
Activity of the disease determined by rheumatologist DAR 1 DAR 2 
2 – low activity 0 0 
3 – moderate activity 1 0 
4 – high activity 0 1 
Table 5. Coding of the categorical variables in the regression analysis. 
The analysis of Table 4 shows that main variable associated with BMD decrease at all 
examined sites of the skeleton is moderate and high disease activity which was determined 
by rheumatologist. Higher BMD values at all examined sites of the skeleton are determined 
by higher BMI of the patients with SpA (positive coefficient of regression). Spine BMD 
(expressed as Z-score) and both femurs BMD (expressed as g/cm2 and Z-score) are 
significantly negatively affected by glucocorticoids. This means that higher cumulative 
glucocorticoid dose is associated with lower BMD at the spine and both femurs. Severe 
limitation of spine movement, assessed by the intermalleolar distance, is the significant 
negative variable for BMD changes at the upper part of the left and right femur (expressed 
as g/cm2 and Z-score). The duration of the disease calculated from the onset of first 
symptoms was a significant variable associated with the changes in spine BMD (expressed 
as Z-score). It should be noted that lengthening of the duration of the disease is associated 
with higher Z-score at the spine (positive coefficient of regression was obtained). Male 
gender is another causative factor significantly positively affecting spine BMD changes 
(expressed as g/cm2). 
To summarise, it should be stated that the decrease of spine BMD is significantly associated 
with moderate and high activity of the disease determined by rheumatologist, and with the 
increase of cumulative dose of glucocorticoids; the decrease of upper part of both femurs 
BMD is associated with moderate and high activity of the disease determined by 
rheumatologist, the increase of cumulative dose of glucocorticoids and severe limitation of 
spine movement assessed by intermalleolar distance. Based on beta coefficients of 
significant variables it might be stated that the most precise prognostic variable for the 
decrease of BMD is increasing activity of the disease in patients with SpA determined by 
rheumatologist. 
Analyzing BMD changes dependence from changes of established significant variables 
subjects of SpA group were allocated into subgroups according to these factors. Allocation 
was based on literature data and trends of changes of BMD and specific factors established 
by our research. 
In order to clarify how BMD changes with the increase of the disease duration (assessed 
from the time of first symptoms) we allocated patients with SpA in three subgroups: 
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patients with the duration of the disease shorter than 100 months; patients with the duration 
of the disease from 100 to 200 months; and patients with the duration of the disease of more 
than 200 months. Results of the comparison BMD (expressed as g/cm2 and Z-score) between 
subgroups presented in Table 6. 
 
BMD 
Duration of the disease from the time of first symptoms 
p Post hoc 
1 2 3 
< 100 months 
(n = 75) 
100-200 months (n = 35) 
> 200 months 
(n = 26) 
BMDS .878 (.105) .852 (.158) .890(.147) .488  
BMDL .886 (.100) .804 (.123) .803(.140) < .001
1>2 (p = .002) 
1>3 (p = .005) 
BMDR .875 (.096) .795 (.138) .782(.128) < .001
1>2 (p = .002) 
1>3 (p = .001) 
ZS -1.311 (.888) -1.468 (1.163) -1.131(1.016) .422  
ZL -.920 (.893) -1.432 (.947) -1.342(.986) .013 1>2 (p = .021) 
ZR -1.004 (.878) -1.489 (1.030) -1.491(.922) .011 1>2 (p = .031) 
Table 6. Comparison of BMD (g/cm2) and Z-score (mean (SD)) between patients with 
various disease duration (assessed from the time of first symptoms). Bone mineral density 
(BMD) expressed as g/cm2 at spine (BMDS), left femur (BMDL) and right femur (BMDR); 
BMD expressed as Z-score in spine (ZS), left femur (ZL) and right femur (ZR). 
Using analysis of variance (ANOVA) it was established that BMD (expressed as g/cm2 and 
Z-score) at the both femurs significantly decreased when duration of the disease increased 
(assessed from the time of first symptoms). BMD at the spine not only decreases with the 
increase of the duration of disease, but even slightly increases, however, not significantly. 
We suppose that this is only „false-positive“ effect occurred due to spine changes specific to 
SpA: syndesmophytes, calcification of longitudinal ligaments and calcification intervertebral 
discs and joint ankylosis in long-term SpA patients, and therefore no significant spine BMD 
(expressed as g/cm2 and Z-score) differences between these subgroups were established 
measuring BMD by DXA anterior-posterior view. No significant BMD differences between 
subgroups of patients allocated according to the duration of the disease assessed from the 
time of diagnosis were established in any sites of the skeleton (all p > .05. data not shown). 
According to these data we may assume that the most significant loss of bone mass takes 
place in the beginning of disease when diagnosis is not established yet. When diagnosis is 
established, etiopathogenetic treatment starts strongly inhibiting local and systemic 
inflammation and associated osteoclast activity and demineralization of the bone tissue. 
Another variable that allows for the suspected decrease of BMD (expressed as g/cm2 and Z-
score) at upper parts of both femurs is decrease in spine movement assessed by the 
intermalleolar distance. When SpA patients were allocated into subgroups according to 
standardized levels of limitation of movement, it was noticed that with the decline of spine 
movement (assessed by the intermalleolar distance) BMD decreased not only at both femurs 
(expressed as g/cm2 and Z-score), but also at the spine (expressed as g/cm2). The lowest 
femur BMD (expressed as g/cm2 and Z-score) was determined in SpA patients with severe 
limitation of spine movement assessed by the intermalleolar distance (Table 7). 
www.intechopen.com
 
Clinical and Molecular Advances in Ankylosing Spondylitis 
 
38
BMD 
Level of limitation of spine movement
p Post hoc 0
(n = 73) 
1
(n = 44) 
2
(n = 19) 
BMDS .899 (.112) .857 (.124) .813 (.171) .019 2<0 (p = .024) 
BMDL .880 (.099) .849 (.116) .730 (.139) < .001 
2<0 (p < .001) 
2<1 (p < .001) 
BMDR .871 (.100) .840 (.103) .698 (.145) < .001 
2<0 (p < .001) 
2<1 (p < .001) 
ZS -1.184 (.929) -1.448 (.877) -1.522 (1.370) .234  
ZL -.980 (.879) -1.145 (.873) -1.692 (1.191) .049 2<0 (p = .009) 
ZR -1.051 (.885) -1.205 (.794) -1.917 (1.238) .002 
2<0 (p < .001) 
2<1 (p = .014) 
Table 7. Comparison of BMD (g/cm2) and Z-score (mean value (SD)) between SpA patients 
allocated according to the established limitation of spine movement assessed by the 
intermalleolar distance 
Bone mineral density (BMD) expressed as g/cm2 at spine (BMDS), left femur (BMDL) and 
right femur (BMDR); BMD expressed as Z-score in spine (ZS), left femur (ZL) and right 
femur (ZR); 0 - mild limitation of movement, 1 – moderate limitation of movement, 2 – 
severe limitation of movement. 
Another significant and clinically important factor associated with BMD changes at the 
spine and both femurs is cumulative dose of GC. It is not known what cumulative dose of 
GC or duration of use of these medications become risk factors for the decrease of BMD. 
Therefore patients were conventionally allocated into 4 subgroups according to the 
following distribution of cumulative doses: untreated patients (n = 46); patients using 
cumulative dose of less than 1 g (n = 34) corresponding use of 5 mg/day during up to 6 
months; patients using cumulative dose from 1 to 10 g (n = 36) corresponding use of 5 
mg/day during up to 5 years; and patients using cumulative dose more than 10 g (n = 20) 
corresponding use of 5 mg/day longer than 5 years. 
 
BMD 
Cumulative glucocorticoid dose
p Post hoc 
1 2 3 4
Untreated
(n = 46) 
< 1g
(n = 34) 
1-10 g
(n = 36) 
>10 g
(n = 20) 
BMDS .869 (.102) .903 (.138) .869 (.126) .844 (.167) .405  
BMDL .881 (.110) .873 (.122) .830 (.106) .769 (.133) .002
4<1 (p = .002) 
4<2 (p = .010) 
BMDR .868 (.112) .856 (.113) .827 (.101) .747 (.150) .001
4<1 (p = .001) 
4<2 (p = .006) 
ZS -1.320 (.933) -1.097 (.975) -1.361 (.960) -1.602 (1.160) .333  
ZL -.871 (.958) -1.076 (.791) -1.270 (.847) -1.586 (1.180) .028 4<1 (p = .024) 
ZR -.962 (.983) -1.186 (.737) -1.291 (.817) -1.757 (1.226) .017 4<1 (p = .009) 
Table 8. Comparison of BMD (g/cm2) and Z-score (mean value (SD)) between SpA patients 
allocated according to the cumulative glucocorticoid dose. Bone mineral density (BMD) 
expressed as g/cm2 at spine (BMDS), left femur (BMDL) and right femur (BMDR); BMD 
expressed as Z-score in spine (ZS), left femur (ZL) and right femur (ZR). 
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Comparison of BMD (expressed as g/cm2 and Z-score) between patients allocated according 
to cumulative glucocorticoid dose is presented in the Table 8. Analysis of the results using 
Turkey HSD test demonstrated that between first three groups (untreated patients, patients 
used < 1g and 1-10g cumulative dose of glucocorticoids) there are no statistically significant 
differences of BMD (expressed as g/cm2 and Z-score) at the lumbar spine and upper part of 
the left and right femur. However, differences presented in the Table 8 are caused by the 
comparison of patients taking a cumulative dose of more than 10 g of glucocorticoids with 
untreated patients. Summarizing these results it may be said that higher than 10 g 
cumulative dose of glucocorticoids is associated with the decrease of BMD (expressed as 
g/cm2 and Z-score) at the upper part of the left and right femur in patients with SpA. 
The most important SpA factor associated with the loss of bone mass is the activity of SpA 
disease. In SpA group there were no patients with inactive disease determined by 
rheumatologist (score of activity = 1), and therefore patients were allocated into three 
subgroups according to the activity of disease: 2 – mild activity, 3 moderate activity, 4 – high 
activity. Comparison BMD between these subgroups presented in the Table 9. 
 
BMD 
Activity of the disease determined by rheumatologist 
p Post hoc 
2 (n = 35) 3 (n = 55) 4 (n = 46) 
BMDS .937 (.112) .878 (.116) .819 (.133) < .001
4<2 (p < .001) 
4<3 (p =.015) 
3<2 (p = .026) 
BMDL .927 (.093) .865 (.110) .771 (.107) < .001
4<2 (p < .001) 
4<3 (p < .001) 
3<2 (p = .007) 
BMDR .909 (.087) .860 (.109) .754 (.113) < .001
4<2 (p < .001) 
4<3 (p < .001) 
3<2 (p = .034) 
ZS -.809 (.899) -1.301 (.837) -1.722 (1.054) < .001
4<2 (p < .001) 
4<3 (p =.025) 
3<2 (p = .016) 
ZL -.538 (.735) -1.054 (.914) -1.680 (.837) < .001
4<2 (p < .001) 
4<3 (p < .001) 
3<2 (p = .005) 
ZR -.683 (.717) -1.092 (.905) -1.787 (.881) < .001
4<2 (p < .001) 
4<3 (p < .001) 
3<2 (p = .028) 
Table 9. Comparison BMD (g/cm2) and Z-score (mean value (SD)) between SpA patients 
allocated according to the activity of the disease determined by rheumatologist Bone 
mineral density (BMD) expressed as g/cm2 at spine (BMDS), left femur (BMDL) and right 
femur (BMDR); BMD expressed as Z-score in spine (ZS), left femur (ZL) and right femur 
(ZR); 2 – mild activity, 3 – moderate activity, 3 – high activity. 
Analysis of the comparison data presented in Table 9 demonstrated that disease activity 
assessment performed by rheumatologist allows to suspect BMD changes in all sites of 
skeleton. In all analyzed sites (in lumbar spine and both femurs BMD expressed as g/cm2 
and Z-score) in patients with lower disease activity (2) BMD was higher in comparison with 
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patients with moderate (3) activity of the disease, and in this group of patients BMD was 
higher than in patients with high (4) activity of the disease. 
3.5 Factors predicting Z-score probability of  ≤ - 2.0 at any site of skeleton 
At the last step of the analysis of the results we performed forward stepwise (Wald) logistic 
regression analysis intended to find out which variables are the most predictive to event 
causing Z-score probability of  - 2 at any site of skeleton. Assigning Z-score  - 2.0 as one 
and Z-score > -2.0 as zero, logistic regression model will predict the probability of the event 
during which coded variable will obtain valuation of 1; in this case the probability will be 
designated as θ. Z-score of ≤-2.0 at least in one area of skeleton was determined in 43 
patients with SpA (31.6 percent of all patients with SpA). 
All variables analyzed in this research were entered into a forward stepwise logistic 
regression model: age, gender, BMI, family history of fractures, disease belonging to SpA 
group, type of joint lesion and physical activity; duration of the disease assessed from the 
time of the onset of first symptoms and from the time of the diagnosis; physical disability 
and immobility indicators: BAS-G, BASFI, HAQ-S, lumbar side flexion, modified Schober’s 
test, tragus to wall distance and intermalleolar distance; indicators of the activity of the 
disease: ESR, CRP, BASDAI and disease activity determined by rheumatologist; cumulative 
dose of glucocorticoids and treatment with TNF-α blockers.  
The following significant variables for event θ remained in the logistic regression model: 
moderate and high activity of the disease determined by rheumatologist, low BMI and 
positive family history of fractures. The results of the last step of logistic regression model 
are presented in Table 10. 
 
 
Indices of the relevance of 
model 
Regressor* 
Coefficient of 
regression (B), 
(standard error) 
Wald 
statistics
p 
Exp 
(B) 
χ2 model compatibility 
criterion p < .001 
 
Hosmer and Lemeshow χ2 
compatibility criterion p = 
.771 
 
Coefficient of 
determination: 
Negelkerke R2 = .407 
DAR  17.852 <.001  
DAR (2) 3.922 (1.091) 13.384 <.001 54.179 
DAR (1) 2.610 (1.077) 5.877 .015 13.602 
BMI -.156 (.052) 9.025 .003 .856 
Positive family 
history of 
fractures 
1.167 (.543) 4.618 .032 3.212 
constant -.528 (1.607) .108 .743 .590 
 
Table 10. Logistic regression analysis of the event when Z-score probability at any site of 
skeleton will be  - 2.0 at the analysis of SpA patient data. * DAR – activity of the disease 
determined by rheumatologist; coding of variables described in the Table 5. 
The analysis demonstrated that correct probabilities for Z-score at any sites of the skeleton 
were established in 75.7 % of respondents. 
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4. Discussion 
Skeletal remodeling in bone growth, maintenance, and repair is tightly regulated by a 
dynamic interaction between osteoclasts and osteoblasts. Recent advances in 
immunopathological mechanism of chronic inflammatory rheumatic disease highlighted the 
altered balance between bone loss and production by inflammation. T cells, natural killers, 
and cytokines that are involved in inflammatory process may also be responsible for the 
bone loss (Ritchlin et al., 2003). Many  investigators have observed decreased BMD of the 
whole skeleton and increased femoral and vertebral fracture risk in patients suffering from 
both RA and SpA in comparison with healthy persons (Lodder, 2004; Huusko, 2001; Grisar, 
2002). Up till now BMD changes were not being compared between SpA and RA patients.  
An interesting observation from our study is that there was no statistically significant 
difference of BMD in any examined part of skeleton between the two groups of diseases, i.e. 
RA and SpA but the BMD difference between the control group and RA and SpA groups 
was statistically significant, the BMD being higher in all examined parts of skeleton of  the 
control group. Analyzing BMD of  SpA, RA and control groups the Z-score of the three 
groups were compared in order to exclude influence of age and gender, known OP risk 
factors,  on BMD. The Z-score in all examined parts was similar for both RA and SpA 
groups while the Z-score difference in the same parts examined between the control group 
and both  patient groups was statistically significant, the Z-score being higher in the control 
group. The findings support the hypothesis that inflammatory environment not only in joint 
synovial tissues but also in bone caused by autoimmune changes in RA and SpA patients 
induces a lot of molecular changes, RANKL and OPG equilibrium derangement and is one 
of the causes provoking not only local but also systemic osteoclastogenesis and related bone 
resorbtion (Suda, 1992; Franck, 2004; Golmia, 2002). The reduced BMD in case of both RA 
and SpA may also be explained by worsened mobility function (Szejnfeld, 1997; Faus-Riera, 
1991), disturbances of calcium and vitamin D metabolism because of intestine injury and 
adverse effect of GC on bone tissue (Lange, 2005; Mielants, 1989). 
Data on comparison of the BMD between healthy persons and patients diagnosed with SpA 
are scarce. As it was mentioned above the BMD of SpA patients was mostly investigated in 
AS. Several researchers have observed decreased BMD in AS patients compared with 
healthy persons (Will, 1989; Devogelaer, 1992; Sampaio-Barros, 2005). K. Dheda and 
colleagues, having examined 20 PsA patients, have not observed any  statistically significant 
BMD reduction in PsA patients compared with healthy persons either in lumbar spine or in 
femur (Dheda et al., 2004). On the contrary B. Frediani and colleagues have found 
statistically significant BMD reduction both in vertebra and femur of PsA patients compared 
with corresponding skeleton parts of the control group (Frediani et al., 2001). Data on 
statistically significant BMD reduction in entire skeleton of EnA patients compared with the 
control group was published  by several authors. (Frei, 2006; Reffitt, 2003). J. Grisar and 
colleagues investigated bone metabolism markers and BMD of AS, PsA and ReA patients. 
The investigators found statistically significant BMD decrease in the proximal femur of AS 
patients compared with PsA patients. There was no statistically significant  difference of 
vertebral BMD of AS patients and both vertebral and proximal femoral BMD of PsA and 
ReA patients compared with the BMD of the control group. J. Grisar and colleagues 
conclude that in all forms of the above mentioned spondyloarthropathies accelerated 
resorbtion of bone tissue prevails regardless of the fact that decreased BMD was not 
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observed in all examined disease patients compared with the control group (Grisar et al., 
2002). We have not found any statistically significant BMD difference in AS, PsA, EnA and 
ReA patients in any part of the skeleton examined.  
In our study we tried to define a correlation  between BMD changes in lumbar spine and 
proximal femur and duration of the SpA.The SpA duration was calculated by the two 
following ways: from manifestation of the first symptoms  and from the moment  of clinical 
diagnosis statement. The results revealed that lenghthening disease duration  calculated 
from manifestation of the symptoms is related to vertebral BMD growth and femoral BMD 
reduction. Agreeing with other authors  (Donnelly, 1994; Reid, 1986; Mullaji, 1994), we think 
that vertebral BMD readings of patients with long disease duration measured by anterior-
posterior view of DXA method are merely „deceptive“. The lumbar spine often shows 
misleading high BMD values due to bridging syndesmophytes and ankylosis, which might 
mask osteoporosis in AS patients with an advanced disease (Donnelly, 1994; Karberg, 2005; 
Mullaji, 1994; Muntean, 2011).  
Our previous investigations showed that SpA patients both with long and short disease 
duration have statistically significant lower proximal femoral and lumbar vertebral BMD 
compared with the control group (Venceviciene et al., 2008). Lengthening disease duration 
calculated from the moment of clinical diagnosis statement had no significant correlation to 
changes of vertebral and proximal femoral BMD. R. Will and colleagues have not found 
significant  difference in the average lumbar vertebral BMD between patients suffering from 
AS longer than 10 years and the control group (Will et al., 1990).  E. S. Meirelles and 
colleagues observed positive correlation between disease duration and changes of proximal 
femoral and lumbar vertebral BMD (Meirelles et al., 1999). Until now only one study that 
quantifies the magnitude of osteoporosis in population of early SpA patients is available 
(Van der Weijden et al., 2011). In this study all patients had a BMD measurement at a 
median of period 6.6 months after diagnosis. This study showed a high prevalence (47%) of 
low BMD in both femur and lumbar spine in SpA patients with early disease. In contrast 
with our study, no significant differences between the two groups with low and normal 
BMD were found in regard to time since diagnosis and disease duration (median of 6.3 
years), counting from the very first symptoms of axial manifestations (Van der Weijden et 
al., 2011). Unfortunately the above mentioned study has some limitations: the BMD of 
patients was not compared with healthy persons. More to the point, a BMD and Z-score 
should be used instead of T-score  to assess BMD changes in males under 50 years of age. 
The fact that low BMD is encountered in a young population with an early disease is very 
interesting. In most other studies, “early” often refers to patients who have not yet 
developed ankylosis or other radiological progression signs, or that these studies made use 
of disease durations as time since diagnosis and then referred to a disease duration of <10 
years (Gratacos, 1999; Toussirot, 2001, Will, 1989). The issue of defining disease duration has 
been often debated in the AS literature. Today, the onset of the first symptoms is considered 
to be most important criteria (Davis et al., 2006). Taking into account the fact that AS is 
usually diagnosed 6-8 years after manifestation of the first symptoms we think that the most 
prominent decrease of the BMD takes place in the early pre-diagnosis period of the disease. 
Etiopathogenetic treatment begun after diagnosing the disease suppresses local and 
systematic inflammation and related activity of osteoclasts together with demineralization 
of the bone tissue.  
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In SpA, especially AS, other potential risk factors for bone loss occur, such as inflammation 
and mechanical factors -rigidity of the spine resulting in limited mobility and reduced 
physical activity due to pain and stiffness. Data about these risk factors, high disease activity 
variables such as ESR, CRP, BASDAI in relation with low BMD levels in different studies are 
not consistently reported (Karberg, 2005; Gratacos, 1999; Toussirot, 2001). 
Acknowledging that high SpA activity is one of the most important risk factors for BMD 
reduction (Gratacos, 1999; Kim, 2006) and there being no currently standardized indicators 
of SpA activity we aimed to define which of the accessible disease activity indicators most 
frequently used in clinical practice might reflect  BMD changes in SpA patients. We assessed 
disease activity on the basis of active disease diagnosis rated by the same rheumatologist, 
acute inflammatory phase indicators, ESR and CRP, and by subjective patient‘s evaluation 
of the disease activity  using results of BASDAI questionnaire (Landewe et al., 2004). We 
found statistically significant association between decreased vertebral and both femoral 
BMD and  moderate or hight  SpA activity rated by the rheumatologist. There was no 
significant correlation between CRB, ESR, BASDAI and BMD changes in the examined 
skeleton parts. 
On the contrary, E. S. Meirelles and colleagues have found no correlation between  disease 
activity rated by the rheumatologist and BMD changes (Meirelles et al., 1999). K. Capaci and 
colleagues has proved that disease activity rated by physician on the basis of radiological 
signs of vertebral and hip destruction extent has no influence on the bone mass of AS 
patients (Capaci et al., 2003). Other authors have made similar conclusions to proving that 
acute inflammatory phase markers found once  do not forecast either progression of 
radiological signs of SpA or reduction of BMD in different parts of skeleton. (Karberg, 2005; 
Toussirot, 2001; Muntean, 2011). Nevertheless, J. Gratacos and colleagues having carried out 
a two year perspective study and assessing AS disease activity by ESR, CRP and IL-6 blood 
concentration  found that the subgroup of active disease patients had statistically significant 
reduction of BMD of femoral neck and lumbar spine but there were no significant BMD 
changes in the examined parts of the subgroup of non-active disease patients. (Gratacos, 
1999). In another study disease activity parameters such as increased CRP and high BASFI 
and BASMI scores, correlated significantly with low bone mass in femoral neck as well as in 
lumbar spine (Van der Weijden et al., 2011). However, at the 12-month follow-up study hip 
bone loss was found to be associated with raised baseline C-reactive protein levels 
(Haugeberg et al., 2010). 
Based on the previous research, as well as on the results of the present study, we conclude 
that active course of the disease and pronounced systemic inflammatory process without 
question has negative influence on BMD by different mechanisms which are insufficiently 
researched up to this time.  We think that the contradiction that exists between our data and 
presented by other authors about the influence of disease activity on BMD changes may 
result from the difference in the groups of patients (the other authors mostly studied only 
AS patients) and methods used to assess disease activity. Furthermore, the role of pro-
inflammatory cytokines might be important for the onset of osteoporosis because increased 
TNF-alpha levels have been found in patients with AS compared with subjects with non-
inflammatory back pain, and correlations have been found between disease activity and 
markers associated with an increased bone metabolism (Lange et al., 2000). We, together 
with other authors think that cross-sectional laboratory acute inflammatory  markers such as 
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CRP or ESR  and results of BASDAI questionnaire which reflects the main SpA symptoms 
during the last week can  not  predict  BMD changes (Karberg, 2005; Speden, 2002; Muntean, 
2011). Only a physician rheumatologist’s assessment of the entire case history including 
clinical, laboratory, radiological signs and taking regular care of the patient may accurately 
determine disease activity in the long course of disease activity. Disease activity according 
to our research data has a significant correlation with bone mass loss both in lumbar 
vertebral and femoral proximal regions.  
We also tried to determine the influence of physical disability and disturbances of mobility 
function on BMD changes in lumbar vertebral and femoral proximal regions. Like other 
investigators we have found that patient’s mobility function worsens with increasing 
duration of the illness (Falkenbach, 2002; Wei, 2007; Karatepe, 2005). It is known  that  SpA 
standardized indicators of spine mobility correlate with radiological  changes such as  
impairment in sacroiliac joints and spine and the latter is an independent factor for the 
prediction of femoral BMD changes (Speden et al., 2002).  We have established that the 
decrease of spine mobility determined by the modified Shober test shows possible reduction 
of femoral BMD. H. J. Baek and colleagues, having divided AS patients into two groups by 
spine flexibility index according to Schober test (correspondingly > 5cm and < 5cm), the 
group of patients with good mobility and the group of patients with bad mobility, have not 
found any BMD difference in lumbar spine between the groups while the proximal femoral 
BMD was statistically significantly lower in the bad mobility group in comparison with the 
good mobility group (Baek et al., 2005). We have obtained similar results by dividing SpA 
patients according to tragus-to-wall distance and lumbar lateral flexion measurement, then 
assessing the decrease in spine flexibility  and comparing it‘s BMD. Statistically significant 
BMD difference was obtained only in the femur. Differently, the decrease in spine flexibility 
was determined by  intermalleolar distance measurement, showed significant BMD 
reduction not only in femur but in spine too.  We failed to find studies assessing correlation 
between spine flexibility indices such as lateral flexion, tragus-to-wall distance, 
intermalleolar distance (measuring spine flexibility in different parts of spine) and BMD 
changes.  
It is worthy to note that many studies assessing mobility and physical disability of SpA 
patients are being carried out  all over the world (Bostan, 2003; Zochling, 2006; Ward, 2002) 
but the research data about dependence of bone mass changes in different regions of 
skeleton on physical disability and disturbances of mobility are scarce and controversial.  
Several scientists insist that disturbances of mobility function have no influence on lowering 
BMD in AS patients (Mitra, 1999; Maillefert, 2001). J. Gratacos and colleagues failed to find 
the correlation between BMD reduction and the results of HAQ-S questionnaire evaluating 
physical disability of SpA patients. (Gratacos et al., 1999). Nevertheless H. Franck and 
colleagues found that patients having decreased BMD in different parts of the skeleton had 
significantly poorer mobility function indices (Schober index and results of BASFI 
questionnaire) in comparison with the group of patients having normal BMD (Franck et al., 
2004). The results of our study however show that lessening of mobility function has no 
influence on spinal BMD. Changes in femoral BMD are best reflected by the physical 
disability of SpA patients assessed using  HAQ-S questionnaire and disturbances of mobility 
function assessed by the BASFI questionnaire.  
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In agreement with other authors (Will, 1989; Mullaji, 1994) we have found that frequency of 
exercise of the patient had no significant  influence on BMD changes in the parts of skeleton 
examined.  
Summing up the results it is possible to state that reduction of BMD correlates with 
disturbances of mobility function that lessens during disease course as demonstrated by the 
results presented above. On the other hand, comparativelly good spine BMD  results  are 
probably „misleading“. We as other researchers (Donnelly, 1994; Reid, 1986) support the 
statement that in the course of the disease, impairment of the spine begins in the form of 
calcification of longitudinal  ligaments and intervertebral discs, formation of 
syndesmophytes and joint ankylosis. Apparently the decrease in spine mobility caused by 
changes in the spine may be associated with  proximal femoral BMD changes. 
The aim of our study was to clear up whether GC and TNF-α blockers can influence BMD 
changes for SpA patients. The effect of GC on bone mass of SpA patients is not sufficiently 
investigated. Some authors are of the opinion that GC cumulative doses is not a factor in the 
successful prognosis of BMD decrease [Bjarnason, 1997; Habtezion, 2002; Millard, 2001). 
Several clinical studies have shown that GC in doses of less than 7,5 mg/d does not incite 
more pronounced bone resorbtion (Bijlsma, 2000; Nishimura, 2000). O. A. Malysheva and 
colleagues have proved that the therapeutic GC dose of  7,5 mg/d has negative influence on 
BMD when being used longer than 48 weeks (Malysheva et al., 2008).  Still A. Savickienė 
and colleagues have found that duration of GC use and their cumulative dose significantly 
correlated with lumbar spine BMD reduction in SpA patients (Savickienė et al., 2003). 
Negative GC influence on bone mass was also described by German researchers having 
determined that cumulative GC dose negatively correlates with BMD changes and serves as 
an independent factor for prognosis of BMD reduction in all parts of skeleton (Pollak, 1998; 
De Jong, 2002).  
Considering the fact that GC treatment schemes (dose and duration of presciption) were 
changed several times we have conditionally divided SpA patients into 4 subgroups 
according to cumulative GC doses. We have compared BMD among the subgroups. We 
have not found statistically significant femoral and vertebral BMD difference among the first 
three subgroups ( patients who have not used GC, used  cumulative GC doses of <1g and 1-
10g ). Proximal femoral BMD of patients who used more than 10g of GC was statistically 
significantly less than BMD of patients who have not used GC. Similar results were obtained 
by the other group of researchers who proved that only cumulative GC doses exceeding 10 
g has significant influence on BMD reduction in all parts of skeleton (Silvennoinen, 1995; 
Von Tirpitz, 1993). 
A new group of drugs blocking cytokin TNF- α used for  SpA treatment are called TNF- α 
blocking agents. This drug is effective in reducing disease symptoms, inflammatory 
processes and joint destruction (Braun, 2002; Brandt, 2000; Baeten, 2001;  Breban, 2002 ; 
Gorman, 2002). It has been shown that TNF-blocking agents not only reduce signs and 
symptoms of disease activity in SpA, but also arrest hip and spine bone loss (Marzo-Ortega, 
2003; Marzo-Ortega, 2005; Demis, 2002). 
We compared BMD readings of patients treated with TNF-α blockers and patients who did 
not received TNF-α blockers and found no statistically significant BMD difference between 
the groups in all examined parts of the skeleton. While statistically significant influence of 
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TNF-α blockers on bone mass was not found it is still not possible to state that these drugs 
have no positive effect on suppression of bone tissue resorbtion. This cross-sectional study 
was not designed as an observation of TNF-α blockers effectiveness. On the other hand 
these drugs are only used to treat SpA of high activity after treatment with other disease 
modifying drugs and in cases with pronounced joint impairment. On the basis of the results 
of this study showing statistically significant negative influence of high disease activity on 
the BMD changes and „deceptive“ BMD spine readings conditioned by long disease 
duration it is possible to assume that these factors could „hide“ positive effect on bone 
caused by the TNF-α blockers. We hope that the further long term longitudinal studies with 
bigger observational cohort will prove the beneficial effect of TNF-α blockers for not merely 
reducing local and systemic inflammation but also their positive influence on the bone 
tissue of SpA patients.  
Summing up all the results it is possible to state that only moderate or high SpA activity 
rated by the rheumatologist and GC cumulative dose are  statistically significant specific 
factors which can predict reduction of BMD of lumbar spine in SpA patients.. It is 
important to note that the lengthening disease duration counted from the beginning of the 
first symptoms relates to augmentation of spinal BMD. Reduction of BMD of both 
proximal femurs was associated with moderate or high SpA activity rated by the 
rheumatologist, severe reduction of spine flexibility assessed by intermalleolar distance 
measurement and GC cumulative doses. The BMI is the only significant variable out of all 
other factors related to spinal and femoral BMD changes. It is necessary to point that 
increased  BMI is related to higher vertebral and femoral BMD readings. The data of this 
study are in agreement with the data presented by the other authors that  low BMI (< 19 
kg/m2) is related to possible nutritional deficiencies of vitamin D, calcium and protein 
and therefore, to BMD reduction (Ravn, 1999; Edelstein, 1993; Cetin, 2001). We have also 
determined the prognostic factors for SpA patients that need to be included into the group 
of reduced BMD (when the Z-score is ≤–2.0 in any part of the skeleton). Results of our 
study show that SpA patients whose disease activity rated by the rheumatologist is 
moderate or high and who have positive family history of OP fractures have a Z-score of ≤–
2.0 found in any investigated part of the skeleton.  
We have proved that SpA disease activity rated by the rheumatologist, spine flexibility 
assessed by intermalleolar distance measurement, cumulative GC doses, BMI, disease 
duration measured from the manifestation of symptoms and family history of OP fractures  
are important for evaluating the risk of BMD reduction for SpA patients. It is valuable  for 
identifying those who should undergo testing  for BMD and for what specific region of 
skeleton,  and also for prescribing effective means for prevention and/or treatment.  
5. Conclusions 
 In patients with spondyloarthropathies BMD (expressed as g/cm2 and Z-score) is the 
same as in patients with rheumatoid arthritis and is significantly lower in comparison 
with BMD of healthy subjects measured at the lumbar spine and upper part of left and 
right femur. 
 Similar BMD changes at the lumbar spine and upper part of left and right femur are 
characteristic to SpA patients with various diseases belonging to SpA group. 
www.intechopen.com
 
Bone Mineral Density Changes in Patients with Spondyloarthropathies 
 
47 
 In SpA patients BMD changes do not depend on the predominant type of joint lesion. 
 Duration of the disease reflects changes in BMD better when it is calculated not from 
the time of the establishment of clinical diagnosis, but from the time of onset of first 
clinical symptoms. Relations between the duration of the disease and BMD changes at 
the lumbar spine and upper part of left and right femur are different: BMD decreases at 
the upper parts of both femurs and increases at the spine with longer duration of the 
disease.  
 High and moderate activity of the disease (established by rheumatologist) is associated 
with the elevated bone resorption at the lumbar spine and upper part of left and right 
femur. The relation between disease activity (which measured by ESR, CRP level and 
BASDAI questionnaire) and BMD decrease in any investigated area of skeletal system 
was not observed. 
 BMD reduction at the lumbar spine and upper parts of both femurs is associated with 
the decrease of mobility of a SpA patient. Intermalleolar distance is the most precise 
indicant reflecting the relation between decrease of physical ability and mobility and 
BMD changes in all investigated areas of skeletal system: at the spine (BMD expressed 
as g/cm2) and at the upper parts of both femurs (BMD expressed as g/cm2 and Z-
score); the lowest BMD at upper parts of both femurs is measured when reduction of 
spine movement is defined as severe. 
 Significant negative association between cumulative dose of glucocorticoids and BMD 
changes at the lumbar spine and upper part of left and right femur were observed: 
BMD at the lumbar spine and upper parts of both femurs decrease with the increase of 
cumulative dose of glucocorticoids. 
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